Market Trends of Iran Insulin Drugs And Delivery Devices Industry
Rising Diabetes Prevalence in Iran
Diabetes has emerged as a critical public health challenge in Iran, driven by a combination of lifestyle changes, demographic shifts, and environmental factors. This persistent metabolic disorder, characterized by elevated blood glucose levels, leads to severe complications affecting various organs and systems. As diabetes prevalence rises, its implications for the insulin drugs and delivery devices market are becoming increasingly significant.
Diabetes is a chronic condition that demands ongoing management to prevent complications such as kidney damage, heart disease, and neuropathy. The rising prevalence of diabetes in Iran is a direct result of unhealthy and sedentary lifestyles, an aging population, urbanization, and other factors. According to the International Diabetes Federation (IDF) Diabetes Atlas, the diabetic population in Iran is projected to increase from 7.17 million in 2030 to 9.55 million by 2045. This sharp rise is indicative of the escalating burden of the disease on the Iranian healthcare system.
The economic implications of the rising prevalence of diabetes are profound. According to IDF projections, diabetes-related health expenditures in Iran are set to increase from USD 9,066.8 million in 2030 to USD 10,024.4 million by 2045. The increased expenditure on diabetes care includes costs associated with insulin drugs and delivery devices. As more patients require insulin therapy, the volume of insulin prescriptions and the demand for related delivery devices, such as insulin pens, syringes, and glucose meters, are expected to grow. Thus, this trend presents opportunities and challenges for pharmaceutical companies and healthcare providers in Iran.
The increasing prevalence of diabetes is directly influencing the demand for insulin drugs and delivery devices. As the number of diabetic patients grows, the need for effective insulin therapies and advanced delivery systems becomes more pronounced. Insulin is a cornerstone of diabetes management, and the demand for traditional and novel insulin formulations is expected to rise correspondingly.
The Insulin Pens Segment is Expected to Witness Highest Growth Rate During the Forecast Period
In recent years, Iran has witnessed a notable shift in the diabetes management landscape, marked by a significant increase in the usage of insulin pens. This shift is attributed to advancements in insulin delivery technology, changes in production capabilities, and evolving patient needs.
Similarly, in December 2023, Iran took a significant step forward in diabetes care with the introduction of a new generation of insulin pens. The launch event, hosted at a pharmaceutical factory in Alborz province, showcased a newly established insulin production line, boasting a capacity to produce between 80,000 and 100,000 insulin pens. This new generation of insulin pens combines short-acting and long-acting insulin to simplify diabetes management for patients. By reducing the need for multiple injections and lowering daily insulin costs, these pens offer a convenient and cost-effective solution compared to traditional vial and syringe methods.
The transition from vial and syringe-based insulin administration to insulin pens has been gradual. According to an article published by IRNA in December 2023, the usage of pen insulin has substantially increased over the years. Such a shift reflects a broader trend toward more user-friendly diabetes management solutions. Insulin pens offer several advantages, including ease of use, accurate dosing, and improved adherence to treatment regimens. As a result, they have become increasingly preferred by both healthcare providers and patients, leading to a marked decline in the use of traditional vial insulins.
The expansion of insulin pen usage in Iran has also prompted production and supply dynamics changes. As reported by Dunyai Ekhtaz in April 2024, the Food and Drug Organization revealed that approximately half of the insulin pens used in the country are produced domestically, while the other half is imported. This dual-source approach helps mitigate supply chain risks and ensures a steady availability of insulin pens for diabetic patients.
The increasing usage of insulin pens in Iran underscores a significant advancement in the management of diabetes, driven by technological innovations and shifts in patient preferences. The recent developments in insulin pen production and supply reflect a broader trend toward more effective and user-friendly diabetes care solutions.
